Name | Dopexamine hydrochloride |
Description | Dopexamine hydrochloride (FPL60278AR) is a β2-adrenergic receptor agonist. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. |
In vitro | Dopexamine, a dopamine analogue, stimulates β-adrenergic as well as dopamine 1 and 2 receptors, offering vasodilatory effects. It effectively mitigates the systemic inflammatory response triggered by endotoxin, including the release of cytokines, the expression of endothelial adhesion molecules, and oxidative stress, without significantly affecting systemic hemodynamics, such as blood pressure or stroke volume. Additionally, dopexamine possesses agonist activity at β2 and dopaminergic receptors, and at dosages that do not impact global hemodynamics or regional microvascular flow, it can diminish tissue leukocyte infiltration and confer protection against organ damage. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 10 mg/mL (23.29 mM)
|
Keywords | Beta Receptor | Adrenergic Receptor | Dopexamine | Inhibitor | Dopexamine Hydrochloride | Dopexamine hydrochloride | inhibit |
Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Isoprenaline hydrochloride | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |